Industry News

Takeda Pharmaceuticals Partners with Wipro to Enable a Global “as-a-service” IT Platform

  • Posted on: 20 May 2014
  • By: PharmaTutor News

(Business Wire India; 20th May, 2014); Wipro Ltd., a leading global Information Technology, Consulting and Outsourcing company today announced a strategic partnership with Takeda Pharmaceutical Company Ltd., the largest pharmaceutical company in Japan and one of the global leaders of the industry.

Ferring launches Guts4life, An Interactive Online Resource for People with Inflammatory Bowel Disease

  • Posted on: 20 May 2014
  • By: PharmaTutor News

(Business Wire India; 19th May, 2014); Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (guts4life.com), a new interactive website with information, support and inspiration for people concerned with Crohn’s disease and ulcerative colitis, conditions known as inflammatory bowel diseases (IBD). IBD describes a range of chronic diseases of the gastrointestinal system characterised by intermittent flares with debilitating symptoms that can affect a patient’s quality of life and lead to emotional distress and social isolation. Guts4life was designed together with IBD patients to provide support and encouragement throughout the IBD journey—from bowel symptom worries, to diagnosis, through managing and living with IBD.

Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area

(Business Wire India; 13th May, 2014); Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corporation (Orion), the largest pharmaceutical company in Finland, today announced a path breaking drug discovery collaboration to discover small molecule inhibitors in neuroscience therapeutic area. The research deal is aimed at developing drug that can benefit large population of people with unmet needs in the pain management area.

Cipla invests 21 million $ to support Alzheimer’s disease drug development

(12th May, 2014); Cipla announced that it is investing 21 million $ in Chase Pharmaceuticals, an early stage drug development company, based in Washington DC. Chase is focused on developing novel approaches to improve treatments for Alzheimer’s disease. It has a unique patented approach and is focused on improving the efficacy, safety and tolerability of existing Alzheimer medications.

ACG's Pithampur Factory Awarded Gold Rating by LEED-India; First in Pharma Industry to Receive the Certification

(PRNewswire; 6th May, 2014); ACG's continued commitment towards sustainability and efforts in building sustainable sites, reducing water and energy consumption, recycling building material and improving indoor environmental quality has now been recognized. Indian Green Building Council (IGBC) LEED®-India has awarded its prestigious Gold rating to ACG's new state-of-the-art capsule manufacturing plant in Pithampur, making it the first factory in Indian pharmaceutical industry to receive this rating.

Around 19 Crore Indians Likely to Suffer from Skin Diseases by 2015 – notes Frost & Sullivan

(Business Wire India; 2nd May, 2014); The skin care segment has shown tremendous growth and emerged as a potential investment area for players in recent years. From treatment of common skin care diseases, the skin care industry has evolved to the age of cosmetic and anti-aging treatments. The overall skin care market is expected to grow with the rise in demand of various skin care services. Factors like global warming, anti-aging solutions, new product innovations, growing media influence, etc. are driving this market. Boosted by growing consumer demand, rise in disposable incomes, lifestyle related disorders, craze for cosmetic surgeries, obsession for young-looking skin, low cost of treatment, and booming medical tourism, the skin care market in India is likely to expand and emerge as a potential investment area for players.

Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference

(30th Apr, 2014);Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 – 21 May in San Diego. IPF is a rare, debilitating and fatal lung disease for which treatment options are limited.

Appointment of Dr. Arun Chandavarkar as CEO and Joint Managing Director at Biocon Ltd.

(28th Apr, 2014); Biocon Ltd., Asia's premier biotechnology company, announced that the Board of Directors of the Company, in their meeting on last thursday, have approved the induction of Dr. Arun Chandavarkar, on to the board of Biocon Limited. He has also been appointed as Chief Executive Officer and Joint Managing Director.

Pages